Rapamycin slows aging in mice.
Level 5 - mechanism / opinion, no new human data
Animal research (mice) without human data
PubMed 22587563 · doi:10.1111/j.1474-9726.2012.00832.x
What was done
Mice were treated with rapamycin (including a cohort starting treatment at 9 months of age) to evaluate whether rapamycin retards broad physiological aging rather than merely preventing lethal neoplastic diseases. Authors evaluated age-dependent changes across multiple tissues (heart, liver, adrenal glands, endometrium, tendon), tracked spontaneous physical activity, and assessed adverse pathological outcomes. Specific sample sizes, dosing regimens, and exact control groupings are not stated in the abstract.
What was found
The abstract reports no numerical data, exact percentages, or effect sizes. It reports qualitatively that rapamycin-treated mice experienced slower age-dependent alterations in the heart, liver, adrenal glands, endometrium, and tendon, and a slower decline in spontaneous activity. However, mice treated from 9 months of age had a significantly higher incidence of testicular degeneration and cataracts.
Why it matters
This study provides evidence in mice that mTOR inhibition delays multi-organ functional and structural aging rather than merely suppressing lethal cancers, while identifying important toxicities that constrain translation.
Limits
Preclinical animal study in mice; findings cannot be directly applied to human aging. The abstract omits sample sizes, dosages, exposure durations, and numerical statistical metrics. Treatment resulted in significant adverse effects including testicular damage and cataracts.
Cited by
- supports Rapamycin administration has been associated with adverse effects including hyperglycemia, testicular degeneration, and cataracts.